Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: J&J Pauses COVID-19 Vaccine Trial After Unexplained Illness

Plus: China Starts Vaccines Pre-Order

Executive Summary

J&J becomes the second company to pause a COVID-19 vaccine trial, releasing few details but emphasizing the measure's precautionary nature.

You may also be interested in...



J&J's Gorsky On Janssen's COVID-19 Vaccine Timeline, Scale-Up and Back Story

The company is on track to provide hundreds of millions of doses of its COVID-19 vaccine in the first half of 2021, Gorsky reaffirmed during the Milken Institute Future of Health Summit.

Lack Of Details On J&J COVID Vaccine Trial Safety Pause Raises ACIP Concerns About Transparency

Patient confidentiality and trial blinding precluded a Janssen official from sharing specifics about the safety event that led to a study enrollment pause, but Advisory Committee on Immunization Practices representatives say the lack of detailed, publicly disclosed information is not helping vaccine confidence.

Coronavirus Update: Trial Of Lilly's Antibody Is Next To Be Paused

NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel